Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
705 (USA) · Dr. Muller
consented 2013-10-14
AEs
2
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-02-13 (study day 123.0); relationship: PROBABLE
mild
assessed
Mild PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-10-28 (study day 15.0); relationship: PROBABLE
Data queries
No data queries.